Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

摘要: All patients receiving endocrine treatment for advanced breast cancer (ABC) eventually progress, resulting in a need new therapies that lack cross-resistance with existing agents. Oestrogen receptor (ER) modulators such as toremifene and raloxifene have poor efficacy following tamoxifen failure, whereas the non-steroidal aromatase inhibitors (AIs), anastrozole letrozole steroidal AI exemestane are effective. Fulvestrant is ER antagonist no agonist effects effective treating who progressed on tamoxifen. AIs replacing first-line treatments ABC adjuvant setting, necessitating re-evaluation of optimal sequencing. Preliminary data suggest tamoxifen, fulvestrant activity hence could be considered use this setting. Due to apparent between AIs, also failure. Clinical trials underway assess most appropriate sequence comparisons major interest.